Molecular pathogenesis of necrotizing fasciitis

Annual Review of Pathology: Mechanisms of Disease

Volumn 5, Issue , 2010, Pages 1-31

  Olsen, Randall J ^a   Musser, James M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Flesh eating disease; Group A Streptococcus; Severe invasive infection

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CLINDAMYCIN; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 1; MATRIX METALLOPROTEINASE; METAL TRANSPORTER OF STREPTOCOCCUS PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PRSA PROTEIN; SPEB PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ALLERGIC GLOMERULONEPHRITIS; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BLOOD CLOTTING DISORDER; CELL ADHESION; CELL INVASION; DEBRIDEMENT; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; ENZYME RELEASE; EPITHELIUM CELL; ERYSIPELAS; FOURNIER GANGRENE; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HOST PATHOGEN INTERACTION; HUMAN; INJURY; MEDICAL HISTORY; MICROBIOLOGICAL EXAMINATION; NECROTIZING FASCIITIS; NONHUMAN; NUTRIENT UPTAKE; PATHOGENESIS; PHENOTYPE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; RHEUMATIC FEVER; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL PHARYNGITIS; STREPTOCOCCUS GROUP A; SYSTEMS BIOLOGY; TISSUE INJURY; ANIMAL; DISEASE MODEL; GENETICS; MICROBIOLOGY; PATHOGENICITY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

ANIMALS; DISEASE MODELS, ANIMAL; FASCIITIS, NECROTIZING; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TRANSCRIPTION, GENETIC; VIRULENCE FACTORS;

EID: 77949890164     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-121808-102135     Document Type: Review

References (150)

1. Krause RM. 2002. Evolving microbes and re-emerging streptococcal disease. Clin. Lab. Med. 22:835-848
2. Tart AH, Walker MJ, Musser JM. 2007. New understanding of the group A Streptococcus pathogenesis cycle. Trends Microbiol. 15:318-325
3. O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, et al. 2007. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin. Infect. Dis. 45:853-862
4. Sharkawy A, Low DE, Saginur R, Gregson D, Schwartz B, et al. 2002. Severe group A streptococcal soft-tissue infections in Ontario: 1992-1996. Clin. Infect. Dis. 34:454-460
5. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5:685-694
6. Luca-Harari B, Darenberg J, Neal S, Siljander T, Strakova L, et al. 2009. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J. Clin. Microbiol. 47:1155-1165
7. Olsen RJ, Shelburne SA, Musser JM. 2009. Molecular mechanisms underlying group A streptococcal pathogenesis. Cell Microbiol. 11:1-12
8. Olsen RJ, Burns KM, Chen L, Kreiswirth BN,Musser JM. 2008. Severe necrotizing fasciitis in a human immunodeficiency virus-positive patient caused by methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 46:1144-1147
9. Nygaard TK, DeLeo FR, Voyich JM. 2008. Community-associated methicillin-resistant Staphylococcus aureus skin infections: advances toward identifying the key virulence factors. Curr. Opin. Infect. Dis. 21:147-152
10. Angoules AG, Kontakis G, Drakoulakis E, Vrentzos G, Granick MS, Giannoudis PV. 2007. Necrotising fasciitis of upper and lower limb: a systematic review. Injury 38(Suppl. 5):S19-26
11. Xu Q, Pichichero ME, Zeng M. 2009. Adherence of Streptococcus pyogenes to human epithelial cells is modulated by Haemophilus influenzae. Scand. J. Infect. Dis. 41:244-251
12. Yeniyol CO, Suelozgen T, Arslan M, Ayder AR. 2004. Fournier's gangrene: experience with 25 patients and use of Fournier's gangrene severity index score. Urology 64:218-222
13. Descamps V, Aitken J, Lee MG. 1994. Hippocrates on necrotising fasciitis. Lancet 344:556
14. Wilson B. 1952. Necrotizing fasciitis. Am. Surg. 18:416-431
15. Wong CH, Yam AK, Tan AB, Song C. 2008. Approach to debridement in necrotizing fasciitis. Am. J. Surg. 196:e19-24
16. Tajiri T, Tate G, Akita H, Ohike N, Masunaga A, et al. 2008. Autopsy cases of fulminant-type bacterial infection with necrotizing fasciitis: group A (beta) hemolytic Streptococcus pyogenes versus Vibrio vulnificus infection. Pathol. Int. 58:196-202
17. Bryant AE, Bayer CR, Chen RY, Guth PH, Wallace RJ, Stevens DL. 2005. Vascular dysfunction and ischemic destruction of tissue in Streptococcus pyogenes infection: the role of streptolysin O-induced platelet/neutrophil complexes. J. Infect. Dis. 192:1014-1022
18. Rieger UM, Gugger CY, Farhadi J, Heider I, Andresen R, et al. 2007. Prognostic factors in necrotizing fasciitis and myositis: analysis of 16 consecutive cases at a single institution in Switzerland. Ann. Plast. Surg. 58:523-530
19. Mehta S, McGeer A, Low DE, Hallett D, Bowman DJ, et al. 2006. Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU. Chest 130:1679-1686
20. Young MH, Aronoff DM, Engleberg NC. 2005. Necrotizing fasciitis: pathogenesis and treatment. Expert Rev. Anti-Infect. Ther. 3:279-294
21. Norrby-Teglund A, Muller MP, McGeer A, Gan BS, Guru V, et al. 2005. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand. J. Infect. Dis. 37:166-172
22. Kaul R McGeer A Low DE Green K Schwartz B. 1997. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am. J. Med. 103. 18-24.
23. Filbin MR, Ring DC,Wessels MR, Avery LL, Kradin RL. 2009. Case records of the Massachusetts General Hospital. Case 2-2009. A 25-year-old man with pain and swelling of the right hand and hypotension. N. Engl. J. Med. 360:281-290
24. Rodriguez RM, Abdullah R, Miller R, Barry L, Lungstras-Bufler K, et al. 2006. A pilot study of cytokine levels and white blood cell counts in the diagnosis of necrotizing fasciitis. Am. J. Emerg. Med. 24:58-61
25. Al-Tamimi HA, Thomas L. 2008. Necrotizing fasciitis caused by group A Streptococcus with no apparent predisposing factors presenting as acute abdomen. Int. J. Infect. Dis. 12:332-333
26. Factor SH, Levine OS, Schwartz B, Harrison LH, FarleyMM,et al. 2003. Invasive group A streptococcal disease: risk factors for adults. Emerg. Infect. Dis. 9:970-977
27. Nuwayhid ZB, Aronoff DM, Mulla ZD. 2007. Blunt trauma as a risk factor for group A streptococcal necrotizing fasciitis. Ann. Epidemiol. 17:878-881
28. Hird B, Byrne K. 1994. Gangrenous streptococcal myositis: case report. J. Trauma 36:589-591
29. Seki M, Saito M, Iida K, Taniai H, Soejima T, et al. 2008. Onset of streptococcal toxic shock syndrome is accelerated by bruising in a mouse model. Microb. Pathog. 44:339-343
30. Beres SB, Richter EW, Nagiec MJ, Sumby P, Porcella SF, et al. 2006. Molecular genetic anatomy of inter-and intraserotype variation in the human bacterial pathogen group A Streptococcus. Proc. Natl. Acad. Sci. USA 103:7059-7064
31. Bryant AE, Bayer CR, Huntington JD, Stevens DL. 2006. Group A streptococcal myonecrosis: Increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. J. Infect. Dis. 193:1685-1692
32. Hamilton SM, Bayer CR, Stevens DL, Lieber RL, Bryant AE. 2008. Muscle injury, vimentin expression, and nonsteroidal anti-inflammatory drugs predispose to cryptic group A streptococcal necrotizing infection. J. Infect. Dis. 198:1692-1698
33. Stevens DL. 1995. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin. Infect. Dis. 21:977-980
34. Aronoff DM, Bloch KC. 2003. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A Streptococcus. Medicine (Baltim.) 82:225-235
35. Dochez R, Avery OT, Lancefield RC. 1919. Studies on the biology of Streptococcus. I. Antigenic pathogenesis research. relationship between strains of Streptococcus haemolyticus. J. Exp. Med. 30:179-213
36. Beres SB, Sesso R, Pinto SW, Hoe NP, Porcella SF, et al. 2008. Genome sequence of a Lancefield group C Streptococcus zooepidemicus strain causing epidemic nephritis: new information about an old disease. PLoS ONE 3:e3026
37. Daneman N, McGeer A, Low DE, Tyrrell G, Simor AE, et al. 2005. Hospital-acquired invasive group A streptococcal infections in Ontario, Canada, 1992-2000. Clin. Infect. Dis. 41:334-342 (Pubitemid 41022110)
38. Cunningham MW. 2000. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13:470-511
39. Aziz RK, Kotb M. 2008. Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg. Infect. Dis. 14:1511-1517
40. Tyrrell GJ, Lovgren M, Kress B, Grimsrud K. 2005. Invasive group A streptococcal disease in Alberta, Canada (2000 to 2002). J. Clin. Microbiol. 43:1678-1683
41. Musser JM, DeLeo FR. 2005. Toward a genome-wide systems biology analysis of host-pathogen interactions in group A Streptococcus. Am. J. Pathol. 167:1461-1472
42. Beres SB, Sylva GL, Barbian KD, Lei B, Hoff JS, et al. 2002. Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc. Natl. Acad. Sci. USA 99:10078-10083
43. McShan WM, Ferretti JJ, Karasawa T, Suvorov AN, Lin S, et al. 2008. Genome sequence of a nephritogenic and highly transformable M49 strain of Streptococcus pyogenes. J. Bacteriol. 190:7773-7785
44. Green NM, Zhang S, Porcella SF, Nagiec MJ, Barbian KD, et al. 2005. Genome sequence of a serotype M28 strain of group A Streptococcus: potential new insights into puerperal sepsis and bacterial disease specificity. J. Infect. Dis. 192:760-770
45. Banks DJ, Porcella SF, Barbian KD, Beres SB, Philips LE, et al. 2004. Progress toward characterization of the group A Streptococcus metagenome: complete genome sequence of a macrolide-resistant serotype M6 strain. J. Infect. Dis. 190:727-738
46. Ferretti JJ, McShan WM, Ajdic D, Savic DJ, Savic G, et al. 2001. Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc. Natl. Acad. Sci. USA 98:4658-4663
47. Smoot JC, Barbian KD, Van Gompel JJ, Smoot LM, Chaussee MS, et al. 2002. Genome sequence and comparative microarray analysis of serotype M18 group A Streptococcus strains associated with acute rheumatic fever outbreaks. Proc. Natl. Acad. Sci. USA 99:4668-4673
48. Nakagawa I, Kurokawa K, Yamashita A, Nakata M, Tomiyasu Y, et al. 2003. Genome sequence of an M3 strain of Streptococcus pyogenes reveals a large-scale genomic rearrangement in invasive strains and new insights into phage evolution. Genome Res. 13:1042-1055
49. Olsen RJ, Sitkiewicz I, Ayeras AA, Beres SB, Green NM, et al. 2009. A naturally occurring single nucleotide change decreases necrotizing fasciitis ("flesh-eating") capacity of group A Streptococcus (GAS). FASEB J. 22:594 (Abstr.)
50. Shelburne SA 3rd, Granville CN, Tokuyama M, Sitkiewicz I, Patel P, Musser JM. 2005. Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva. Infect. Immun. 73:4723-4731
51. Shelburne SA, Sumby P, Sitkiewicz I, Granville CN, DeLeo FR, Musser JM. 2005. Central role of a two-component gene regulatory system of previously unknown function in pathogen persistence in human saliva. Proc. Natl. Acad. Sci. USA 102:16037-16042
52. Beres SB, Sylva GL, Sturdevant DE, Granville CN, Liu M, et al. 2004. Genome-wide molecular dissection of serotype M3 group A Streptococcus strains causing two epidemics of invasive infections. Proc. Natl. Acad. Sci. USA 101:11833-11838
53. Sumby P, BarbianKD,Gardner DJ, Whitney AR,WeltyDM,et al. 2005. Extracellular deoxyribonuclease made by group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response. Proc. Natl. Acad. Sci. USA 102:1679-1684
54. Tyrrell GJ, Lovgren M, Forwick B, Hoe NP, Musser JM, Talbot JA. 2002. M types of group A streptococcal isolates submitted to the National Center for Streptococcus (Canada) from 1993 to 1999. J. Clin. Microbiol. 40:4466-4471
55. Ma Y, Bryant AE, Salmi DB, Hayes-Schroer SM,McIndoo E, et al. 2006. Identification and characterization of bicistronic speB and prsA gene expression in the group A Streptococcus. J. Bacteriol. 188:7626-7634
56. Lukomski S, Montgomery CA, Rurangirwa J, Geske RS, Barrish JP, et al. 1999. Extracellular cysteine protease produced by Streptococcus pyogenes participates in the pathogenesis of invasive skin infection and dissemination in mice. Infect. Immun. 67:1779-1788
57. Sumby P, Zhang S, Whitney AR, Falugi F, Grandi G, et al. 2008. A chemokine-degrading extracellular protease made by group A Streptococcus alters pathogenesis by enhancing evasion of the innate immune response. Infect. Immun. 76:978-985
58. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, et al. 2004. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 305:1283-1286
59. Taylor FB Jr, Bryant AE, Blick KE, Hack E, Jansen PM, et al. 1999. Staging of the baboon response to group A streptococci administered intramuscularly: a descriptive study of the clinical symptoms and clinical chemical response patterns. Clin. Infect. Dis. 29:167-177
60. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, et al. 1989. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N. Engl. J. Med. 321:1-7
61. Hoe NP, Fullerton KE, Liu M, Peters JE, Gackstetter GD, et al. 2003. Molecular genetic analysis of 675 group A Streptococcus isolates collected in a carrier study at Lackland Air Force Base, San Antonio, Texas. J. Infect. Dis. 18 8:818-827
62. Courtney HS, Hasty DL, Dale JB. 2002. Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. Ann. Med. 34:77-87
63. Hanski E, Caparon M. 1992. Protein F, a fibronectin-binding protein, is an adhesin of the group A Streptococcus pyogenes. Proc. Natl. Acad. Sci. USA 89:6172-6176
64. Gillen CM, Courtney HS, Schulze K, Rohde M, Wilson MR, et al. 2008. Opacity factor activity and epithelial cell binding by the serum opacity factor protein of Streptococcus pyogenes are functionally discrete. J. Biol. Chem. 283:6359-6366
65. Courtney HS, Hasty DL, Dale JB. 2003. Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect. Immun. 71:5097-5103
66. Schulze K, Medina E, Guzman CA. 2006. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain. Vaccine 24:1446-1450
67. Mora M, Bensi G, Capo S, Falugi F, Zingaretti C, et al. 2005. Group A Streptococcus produce piluslike structures containing protective antigens and Lancefield T antigens. Proc. Natl. Acad. Sci. USA 102:15641-15646
68. Lizano S, Luo F, Bessen DE. 2007. Role of streptococcal T antigens in superficial skin infection. J. Bacteriol. 189:1426-1434
69. Falugi F, Zingaretti C, Pinto V, Mariani M, Amodeo L, et al. 2008. Sequence variation in group A Streptococcus pili and association of pilus backbone types with Lancefield T serotypes. J. Infect. Dis. 198:1834-1841
70. Margarit I, Rinaudo CD, Galeotti CL, Maione D, Ghezzo C, et al. 2009. Preventing bacterial infections with pilus-based vaccines: the group B Streptococcus paradigm. J. Infect. Dis. 199:108-115
71. Sitkiewicz I, Nagiec MJ, Sumby P, Butler SD, Cywes-Bentley C, Musser JM. 2006. Emergence of a bacterial clone with enhanced virulence by acquisition of a phage encoding a secreted phospholipase A2. Proc. Natl. Acad. Sci. USA 103:16009-16014
72. Rodriguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, et al. 2006. Characterization and identification of vaccine candidate proteins through analysis of the groupAStreptococcus surface proteome. Nat. Biotechnol. 24:191-197
73. Rodriguez-Ortega MJ, Luque I, Tarradas C, Barcena JA. 2008. Overcoming function annotation errors in the gram-positive pathogen Streptococcus suis by a proteomics-driven approach. BMC Genomics 9:588
74. Nyberg P, Sakai T, Cho KH, Caparon MG, Fassler R, Bjorck L. 2004. Interactions with fibronectin attenuate the virulence of Streptococcus pyogenes. EMBO J. 23:2166-2174
75. Virtaneva K, Porcella SF, Graham MR, Ireland RM, Johnson CA, et al. 2005. Longitudinal analysis of the group A Streptococcus transcriptome in experimental pharyngitis in cynomolgus macaques. Proc. Natl. Acad. Sci. USA 102:9014-9019
76. Gough H, Luke GA, Beeley JA, Geddes DA. 1996. Human salivary glucose analysis by high-performance ion-exchange chromatography and pulsed amperometric detection. Arch. Oral. Biol. 41:141-145
77. Shelburne SA 3rd, Fang H, Okorafor N, Sumby P, Sitkiewicz I, et al. 2007. MalE of group A Streptococcus participates in the rapid transport of maltotriose and longer maltodextrins. J. Bacteriol. 189:2610-2617
78. Shelburne SA 3rd, Keith D, Horstmann N, Sumby P, Davenport MT, et al. 2008. A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus. Proc. Natl. Acad. Sci. USA 105:1698-1703
79. Hollingshead SK, Simecka JW, Michalek SM. 1993. Role of M protein in pharyngeal colonization by group A streptococci in rats. Infect. Immun. 61:2277-2283
80. Ashbaugh CD, Warren HB, Carey VJ, Wessels MR. 1998. Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection. J. Clin. Investig. 102:550-560
81. Lancefield RC. 1962. Current knowledge of type-specificMantigens of groupAstreptococci. J. Immunol. 89:307-313
82. Fischetti VA. 1977. StreptococcalMprotein extracted by nonionic detergent. II. Analysis of the antibody response to the multiple antigenic determinants of the M-protein molecule. J. Exp. Med. 146:1108-1123
83. Dale JB. 2008. Current status of group A streptococcal vaccine development. Adv. Exp. Med. Biol. 609:53-63
84. Cleary PP, Prahbu U, Dale JB, Wexler DE, Handley J. 1992. Streptococcal C5a peptidase is a highly specific endopeptidase. Infect. Immun. 60:5219-5223
85. Park HS, Cleary PP. 2005. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect. Immun. 73:7878-86
86. Brown CK, Gu ZY, Matsuka YV, Purushothaman SS,Winter LA, et al. 2005. Structure of the streptococcal cell wall C5a peptidase. Proc. Natl. Acad. Sci. USA 102:18391-18396
87. Akesson P, Sjoholm AG, Bjorck L. 1996. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J. Biol. Chem. 271:1081-1088
88. Egesten A, Eliasson M, Johansson HM, Olin AI, Morgelin M, et al. 2007. The CXC chemokine MIG/CXCL9 is important in innate immunity against Streptococcus pyogenes. J. Infect. Dis. 195:684-693
89. Hoe NP, Ireland RM, DeLeo FR, Gowen BB, Dorward DW, et al. 2002. Insight into the molecular basis of pathogen abundance: Group A Streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells. Proc. Natl. Acad. Sci. USA 99:7646-7651
90. Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, et al. 2006. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr. Biol. 16:396-400
91. Osterlund A, Popa R, Nikkila T, Scheynius A, Engstrand L. 1997. Intracellular reservoir of Streptococcus pyogenes in vivo: a possible explanation for recurrent pharyngotonsillitis. Laryngoscope 107:640-647
92. Wang B, Cue D, Cleary PP. 2006. Intracelluar invasion by Streptococcus pyogenes: invasins, host receptors, and relevance to human disease. In Gram-Positive Pathogens, ed. V Fischetti, RP Novick, JJ Ferretti, DA Portnoy, JI Rodd, pp. 29-36.Washington, DC: ASM
93. Wang B, Li S, Southern PJ, Cleary PP. 2006. Streptococcal modulation of cellular invasion via TGF-?1 signaling. Proc. Natl. Acad. Sci. USA 103:2380-85
94. Nyberg P, Rasmussen M, Von Pawel-Rammingen U, Bjorck L. 2004. SpeB modulates fibronectindependent internalization of Streptococcus pyogenes by efficient proteolysis of cell-wall-anchored protein F1. Microbiology 150:1559-1569
95. Lovkvist L, Sjolinder H, Wehelie R, Aro H, Norrby-Teglund A, et al. 2008. CD46 contributes to the severity of group A streptococcal infection. Infect. Immun. 76:3951-3958
96. Cockerill FR 3rd, Schlievert PM, Musser JM. 1998. Epidemiology of invasive streptococcal infections. J. Infect. Dis. 177:1773-1774
97. Hidalgo-Grass C, Mishalian I, Dan-Goor M, Belotserkovsky I, Eran Y, et al. 2006. A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues. EMBO J. 25:4628-4637
98. Soehnlein O, Oehmcke S, Ma X, Rothfuchs AG, Frithiof R, et al. 2008. Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein. Eur. Respir. J. 32:405-412
99. Lei B, DeLeo FR, HoeNP, Graham MR,Mackie SM, et al. 2001. Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis. Nat. Med. 7:1298-1305
100. von Pawel-Rammingen U, Johansson BP, Bjorck L. 2002. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 21:1607-1615
101. Akesson P Moritz L Truedsson M Christensson B Von Pawel-Rammingen U 2006. IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection. Infect. Immun. 74. 497-503.
102. Soderberg JJ, Engstrom P, von Pawel-Rammingen U. 2008. The intrinsic immunoglobulin G endopeptidase activity of streptococcal Mac-2 proteins implies a unique role for the enzymatically impaired Mac-2 protein of M28 serotype strains. Infect. Immun. 76:2183-2188
103. Nandakumar KS, Johansson BP, Bjorck L, Holmdahl R. 2007. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo. Arthritis Rheum. 56:3253-3260
104. Wenig K, Chatwell L, von Pawel-Rammingen U, Bjorck L, Huber R, Sondermann P. 2004. Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. Proc. Natl. Acad. Sci USA 101:17371-17376
105. Stock AH, Uriel J, Grabar P. 1961. Esterase in extracellular concentrates of group A streptococci and the homologous antibody. Nature 192:434-435
106. Liu M, Zhu H, Zhang J, Lei B. 2007. Active and passive immunizations with the streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci. Infect. Immun. 75:3651-3657
107. Wessels MR. 2005. Streptolysin S. J. Infect. Dis. 192:13-15
108. Chiang-Ni C,Wu JJ. 2008. Effects of streptococcal pyrogenic exotoxin B on pathogenesis of Streptococcus pyogenes. J. Formos. Med. Assoc. 107:677-685
109. Burns EH Jr, Marciel AM, Musser JM. 1996. Activation of a 66-kDa human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease. Infect. Immun. 64:4744-4750
110. Sakurai A, Okahashi N, Maruyama F, Ooshima T, Hamada S, Nakagawa I. 2008. Streptococcus pyogenes degrades extracellular matrix in chondrocytes via MMP-13. Biochem. Biophys. Res. Commun. 373:450-454
111. Tamura F, Nakagawa R, Akuta T, Okamoto S, Hamada S, et al. 2004. Proapoptotic effect of proteolytic activation of matrix metalloproteinases by Streptococcus pyogenes thiol proteinase (Streptococcus pyrogenic exotoxin B). Infect. Immun. 72:4836-4847
112. Herwald H, Cramer H, Morgelin M, Russell W, Sollenberg U, et al. 2004.Mprotein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 116:367-379
113. Sanderson-Smith ML, Dinkla K, Cole JN, Cork AJ, Maamary PG, et al. 2008. M protein-mediated plasminogen binding is essential for the virulence of an invasive Streptococcus pyogenes isolate. FASEB J. 22:2715-2722
114. Khil J, Im M, Heath A, Ringdahl U, Mundada L, et al. 2003. Plasminogen enhances virulence of group A streptococci by streptokinase-dependent and streptokinase-independent mechanisms. J. Infect. Dis. 188:497-505
115. Ikebe T, Endoh M, Watanabe H. 2005. Increased expression of the ska gene in emm49-genotyped Streptococcus pyogenes strains isolated from patients with severe invasive streptococcal infections. Jpn. J. Infect. Dis. 58:272-275 (Pubitemid 41614736)
116. McKay FC, McArthur JD, Sanderson-Smith ML, Gardam S, Currie BJ, et al. 2004. Plasminogen binding by group A streptococcal isolates from a region of hyperendemicity for streptococcal skin infection and a high incidence of invasive infection. Infect. Immun. 72:364-370
117. McArthur JD McKay FC Ramachandran V Shyam P Cork AJ et al. 2008 Allelic variants of streptokinase from Streptococcus pyogenes display functional differences in plasminogen activation, FASEB J. 22. 3146-3153
118. Edwards RJ,TaylorGW,Ferguson M, Murray S, Rendell N, et al. 2005. Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J. Infect. Dis. 192:783-790
119. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM. 2006. Genome-wide analysis of group A streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog. 2:e5
120. Engleberg NC, Heath A, Miller A, Rivera C, DiRita VJ. 2001. Spontaneous mutations in the CsrRS two-component regulatory system of Streptococcus pyogenes result in enhanced virulence in a murine model of skin and soft tissue infection. J. Infect. Dis. 183:1043-1054
121. Leday TV, Gold KM, Kinkel TL, Roberts SA, Scott JR, McIver KS. 2008. TrxR, a new CovR-repressed response regulator that activates the Mga virulence regulon in group A Streptococcus. Infect. Immun. 76:4659-4668
122. Dalton TL, Scott JR. 2004. CovS inactivates CovR and is required for growth under conditions of general stress in Streptococcus pyogenes. J. Bacteriol. 186:3928-3937
123. Gryllos I, Grifantini R, Colaprico A, Jiang S, Deforce E, et al. 2007. Mg2+ signaling defines the group A streptococcal CsrRS (CovRS) regulon. Mol. Microbiol. 65:671-683
124. Roberts SA, Scott JR. 2007. RivR and the smallRNARivX: the missing links between theCovRregulatory cascade and the Mga regulon. Mol. Microbiol. 66:1506-1522
125. Bryant AE. 2003. Biology and pathogenesis of thrombosis and procoagulant activity in invasive infections caused by group A streptococci and Clostridium perfringens. Clin. Microbiol. Rev. 16:451-462
126. Sun H,Wang X, Degen JL, Ginsburg D. 2009. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 113:1358-1364
127. Shannon O, Hertzen E, Norrby-Teglund A, Morgelin M, Sjobring U, Bjorck L. 2007. Severe streptococcal infection is associated with M protein-induced platelet activation and thrombus formation. Mol. Microbiol. 65:1147-1157
128. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, et al. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:699-709
129. McNamara C, Zinkernagel AS, Macheboeuf P, Cunningham MW, Nizet V, Ghosh P. 2008. Coiled-coil irregularities and instabilities in group A Streptococcus M1 are required for virulence. Science 319:1405-1408
130. Wang X, Lin X, Loy JA, Tang J, Zhang XC. 1998. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science 281:1662-1665 (Pubitemid 128725547)
131. Graham MR, Smoot LM, Migliaccio CA, Virtaneva K, Sturdevant DE, et al. 2002. Virulence control in group A Streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modeling. Proc. Natl. Acad. Sci. USA 99:13855-13860
132. Loughman JA, Caparon M. 2006. Regulation of SpeB in Streptococcus pyogenes by pH and NaCl: a model for in vivo gene expression. J. Bacteriol. 188:399-408
133. Kansal RG, Nizet V, Jeng A, Chuang WJ, Kotb M. 2003. Selective modulation of superantigen-induced responses by streptococcal cysteine protease. J. Infect. Dis. 187:398-407
134. Chaussee MS, Sylva GL, Sturdevant DE, Smoot LM, Graham MR, et al. 2002. Rgg influences the expression of multiple regulatory loci to coregulate virulence factor expression in Streptococcus pyogenes. Infect. Immun. 70:762-770
135. Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, et al. 2007. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat. Med. 13:981-985
136. Johansson L, Thulin P, Sendi P, Hertzen E, Linder A, et al. 2008. LL-37 in severe Streptococcus pyogenes soft tissue infections. Infect. Immun. 76:3399-3404
137. Hollands A, Aziz RK, Kansal R, Kotb M, Nizet V, Walker MJ. 2008. A naturally occurring mutation in ropB suppresses SpeB expression and reduces M1T1 group A streptococcal systemic virulence. PLoS ONE 3:e4102
138. Cole JN, McArthur JD, McKay FC, Sanderson-Smith ML, Cork AJ, et al. 2006. Trigger for group A streptococcal M1T1 invasive disease. FASEB J. 20:1745-1747
139. Kazmi SU, Kansal R, Aziz RK, Hooshdaran M, Norrby-Teglund A, et al. 2001. Reciprocal, temporal expression of SpeA and SpeB by invasive M1T1 group A streptococcal isolates in vivo. Infect. Immun. 69:4988-4995
140. Dmitriev AV, McDowell EJ, Chaussee MS. 2008. Inter-and intraserotypic variation in the Streptococcus pyogenes Rgg regulon. FEMS Microbiol. Lett. 284:43-51
141. Cole JN, Aquilina JA, Hains PG, Henningham A, Sriprakash KS, et al. 2007. Role of group A Streptococcus HtrA in the maturation of SpeB protease. Proteomics 7:4488-4498
142. Akesson P, Rasmussen M, Mascini E, von Pawel-Rammingen U, Janulczyk R, et al. 2004. Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease. J. Infect. Dis. 189:797-804
143. Basma H, Norrby-Teglund A, Guedez Y, McGeer A, Low DE, et al. 1999. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect. Immun. 67:1871-1877
144. Maripuu L, Eriksson A, Eriksson B, Pauksen K, Holm S, Norgren M. 2007. Dynamics of the immune response against extracellular products of group A streptococci during infection. Clin. Vaccine Immunol. 14:44-51
145. Kotb M, Norrby-Teglund A, McGeer A, El-Sherbini H, Dorak MT, et al. 2002. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat. Med. 8:1398-1404
146. Norrby-Teglund A, Thulin P, Gan BS, Kotb M, McGeer A, et al. 2001. Evidence for superantigen involvement in severe group A streptococcal tissue infections. J. Infect. Dis. 184:853-860
147. Ulrich RG. 2008. Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock. J. Immune-Based Ther. Vaccines 6:8
148. Lamagni TL, Neal S, Keshishian C, Alhaddad N, George R, et al. 2008. Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerg. Infect. Dis. 14:202-209
149. Daneman N, Green KA, Low DE, Simor AE,Willey B, et al. 2007. Surveillance for hospital outbreaks of invasive group A streptococcal infections in Ontario, Canada, 1992 to 2000. Ann. Intern. Med. 147:234-241
150. Laupland KB, Davies HD, Low DE, Schwartz B, Green K, McGeer A. 2000. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics 105:E60